Skip to main content

Table 2 Study characteristics of included studies

From: Transcriptomic changes in peripheral blood mononuclear cells with weight loss: systematic literature review and primary data synthesis

Study Study design Sample size Populationa Intervention duration Intervention description RNA extraction Microarray Weight changea Transcript responseb, c Pathway responseb, d
Effect of intervention HR vs LR Effect of intervention HR vs LR
Crujeiras et al. 2008 [21] Cohort 9 44.8 ± 5.2 year, BMI: 44.8 (5.2) kg/m2, 100% male, 100% Caucasian 8 weeks 35% energy restriction, 55% carbohydrates, 30% lipids, 15% protein Trizol Agilent Human 1A Oligo V2 − 8.9 ± 1.5 % 158 increased
227 decreasede
NA NA 7e
Harvie et al. 2016 [22] Cohort 20 (HR = 7) 40.3 ± 3.2 years, BMI: 28.3 (3.1) kg/m2, 100% female, 96% Caucasian 4–5 weeks (1 full menstrual cycle) Overall 25% energy restriction with 2 consecutive days 65% energy restriction, 5 days no restriction, restriction days—100 g carbohydrates and 50 g protein, non-restricted days—45% low-GI carbohydrates, 30% lipids, 25% protein RNeasy plus kit Affymetrix U133 plus2 − 3.3 kg 0 0 8 20
Pinhel et al. 2017 [23] and Pinhel et al. 2018 [27] Cohort 13 39 ± 9 years, BMI: 42.5 (7.0) kg/m2, 100% female, ethnicity NA 6 months Roux-en-Y gastric bypass surgery Phenol/chlorform Illumina HumanHT-12 V4 − 28.8 kg 7 increased
21 decreased
NA 13 NA
Rendo-Urteaga et al. 2015 [24] Cohort 12 (HR = 6) 13.17 ± 0.98f years, BMI-SDS: HR: 3.10 (0.54), LR 4.08 (0.43)f, 100% male, ethnicity NA 10 weeks Between 1300 and 9204 kcal/day calculated based on energy requirements and severity of obesity Trizol Affymetrix Human 1.1 ST HR: − 4.47 kg (0.23)f LR: + 0.75 kg 372 increased
456 decreased
0 increased in HR
23 decreased in HR
53 21
Samblas et al. 2018 [25] Randomised control trialg Discovery = 24, validation = 37 48.4 ± 3.5 years, BMI: discovery: HR: 34.9 (3.0) kg/m2, LR: 37.0 (2.1) kg/m2, validation: HR: 33.8 (3.6) kg/m2 LR: 36.1 (5.0) kg/m2, 54% male, ethnicity NA 6 months 30% energy restriction, 40% carbohydrates, 30% lipids, 30% protein Trizol Illumina HumanHT-12 V4 Discovery:
HR: − 10.5% ± 1.8%, LR: − 5.9% ± 1.7%
Validation:
HR: − 9.5% ± 2.0%, LR: − 5.7% ± 2.1%
NA 20 increased in HR
136 decreased in HRe
NA NA
van Bussel et al. 2019 [26] Randomised Control Trial 40 60 (50–65)h years, BMI: 29.2 (3.0) kg/m2, 52% male, 100% Caucasian 12 weeks 20% energy restriction, 50% carbohydrates, 35% lipids, 15% protein Trizol Affymetrix Human 1.1 ST − 5.6 ± 2.9 kg 0 NA 15 NA
  1. aResults are presented as mean (SD) unless otherwise stated
  2. bresults from quantitative analysis conducted as part of this review unless otherwise stated
  3. ctranscriptomic response describes transcripts that were significantly differentially expressed defined as an absolute fold change > 1.2 or < − 1.2 and adjusted p value < 0.05
  4. dpathway response describes wikipathways that were overrepresented defined as pathways with a z-score < 1.96 and 5 or more genes in the pathway with an unadjusted p value < 0.05
  5. edata reported in article
  6. fdata presented as mean (standard error of the mean)
  7. gresults of intervention and control pooled for transcriptomic analysis
  8. h results presented as mean (range). HR high responders defined as > 5% body weight lost over the intervention period, LR low responders, NA not available, BMI-SDS BMI standard deviation score